Table 1.
Main characteristics of male and female patients at baseline and at scheduled follow-ups
| Males (n = 154) | Females (n = 161) | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| Baseline | 4 months | 8 months | 12 months | Baseline | 4 months | 8 months | 12 months | |
| Age (years) | 59.4 ± 8.1 | – | – | – | 59.7 ± 8.9 | – | – | – |
| Therapy M/SU + M/SU/other (%) | 53.9/43.5/1.9/0.6 | – | – | – | 41.2/55.6/3.1/0* | – | – | – |
| Diabetes duration (years) | 10.4 ± 7.4 | – | – | – | 12.2 ± 7.8* | – | – | – |
| Weight (kg) | 102.3 ± 17.5 | 98.1 ± 17 | 97.5 ± 16.2 | 97.3 ± 16.3 | 89.4 ± 16.7 | 85.2 ± 16.4 | 83.6 ± 15.9 | 83.7 ± 16.5 |
| BMI (kg/m2) | 33.3 ± 5.4 | 31.9 ± 5.2 | 31.7 ± 4.9 | 31.6 ± 5 | 34.4 ± 6.3 | 32.7 ± 6.2 | 32.3 ± 6.2 | 32.3 ± 6.5 |
| Fasting plasma glucose (mmol/L) | 10.3 ± 2.8 | 8.5 ± 2.6 | 8.5 ± 2.2 | 8.4 ± 2.4 | 9.7 ± 2.4* | 8.6 ± 2.5 | 8.6 ± 2.5 | 8.6 ± 2.4 |
| HbA1c (%) | 8.8 ± 1.2 | 7.5 ± 1.1 | 7.6 ± 1.3 | 7.5 ± 1.1 | 8.7 ± 1.0 | 7.7 ± 1.1 | 7.7 ± 1.2 | 7.6 ± 1.1 |
| HOMA-B** | 2.97 (2.20) | 4.62 (4.52) | 3.54 (5.16) | 4.05 (6.07) | 2.84 (2.33) | 3.29 (4.24) | 3.89 (3.60) | 3.13 (2.60) |
Notes:
*
P < 0.05 versus males;
**
obtained in 60 males and in 55 females, expressed as median value (interquartile range).
Abbreviations: n, number; M, metformin; SU, metformin + sulphonylureas; BMI, body mass index; HbA1c, hemoglobin A1c; HOMA-B, homeostasis model assessment-B.